Oppenheimer Reaffirms Outperform Rating for Biogen (NASDAQ:BIIB)
Biogen (NASDAQ:BIIB – Get Free Report)‘s stock had its “outperform” rating restated by analysts at Oppenheimer in a note issued to investors on Tuesday, Benzinga reports. They presently have a $295.00 price target on the biotechnology company’s stock. Oppenheimer’s price objective suggests a potential upside of 19.25% from the stock’s previous close. Several other equities […]